Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Entecavir

FDA-approved product (tablet, oral), marketed as Baraclude, Entecavir.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Entecavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF10; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Entecavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Entecavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

    NCT07797231 · start 2026-09

    Registered record
    Registry ID
    NCT07797231
    Conditions
    Chronic Hepatitis B
    Interventions
    TQA3605 tablets Placebo; TQA3605 tablets; Entecavir dispersible tablets; Tenofovir Disoproxil Fumarate Tablets; Tenofovir Alafenamide Fumarate Tablets; Tenofovir Amibufenamide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2029-10
    Enrolment
    930

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionTQA3605 tablets Placebo; TQA3605 tablets; Entecavir dispersible tablets; Tenofovir Disoproxil Fumarate Tablets +2 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy

    NCT07145268 · start 2025-09-01

    Registered record
    Registry ID
    NCT07145268
    Conditions
    Liver Fibroses; HBV (Hepatitis B Virus)
    Interventions
    Entecavir (ETV); Zinc (zinc sulphate)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2026-09
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Fibroses; HBV (Hepatitis B Virus)
    InterventionEntecavir (ETV); Zinc (zinc sulphate)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.

    NCT07169656 · start 2024-06-03

    Registered record
    Registry ID
    NCT07169656
    Conditions
    Chronic Hepatitis b
    Interventions
    ETV,TDF,TAF,TMF; Peginterferon α-2b injection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-06-03
    Completion
    2032-12-31
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis b
    InterventionETV,TDF,TAF,TMF; Peginterferon α-2b injection
    PhaseNot recorded
    Registry statusRecruiting

  • Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

    NCT05905172 · start 2023-08-12

    Registered record
    Registry ID
    NCT05905172
    Conditions
    Liver Fibrosis
    Interventions
    Hydronidone capsules; The placebo capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-08-12
    Completion
    2028-10-20
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Fibrosis
    InterventionHydronidone capsules; The placebo capsules
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB

    NCT05484466 · start 2022-11-11

    Registered record
    Registry ID
    NCT05484466
    Conditions
    Hepatitis B, Chronic
    Interventions
    ZM-H1505R; ZM-H1505R placebo; Baraclude
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-11-11
    Completion
    2024-12-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionZM-H1505R; ZM-H1505R placebo; Baraclude
    PhasePhase 2
    Registry statusUnknown

  • Antiviral Therapy for Patients With Chronic Hepatitis B Infection

    NCT05382351 · start 2022-05-10

    Registered record
    Registry ID
    NCT05382351
    Conditions
    Chronic Hepatitis B Virus Infection
    Interventions
    Entecavir; Entecavir combined with Tenofovir Amibufenamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-05-10
    Completion
    2024-12-31
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B Virus Infection
    InterventionEntecavir; Entecavir combined with Tenofovir Amibufenamide
    PhasePhase 2
    Registry statusUnknown

  • Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

    NCT05182463 · start 2022-01-08

    Registered record
    Registry ID
    NCT05182463
    Conditions
    Hepatitis B, Chronic
    Interventions
    Peginterferon Alfa-2B; Nucleoside Analogs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-01-08
    Completion
    2029-11-30
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionPeginterferon Alfa-2B; Nucleoside Analogs
    PhasePhase 4
    Registry statusRecruiting

  • A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

    NCT05123599 · start 2021-12-06

    Registered record
    Registry ID
    NCT05123599
    Conditions
    Hepatitis B, Chronic
    Interventions
    JNJ-73763989; JNJ-64300535; ETV monohydrate; Tenofovir disoproxil; TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-12-06
    Completion
    2024-06-26
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionJNJ-73763989; JNJ-64300535; ETV monohydrate; Tenofovir disoproxil +1 more
    PhasePhase 1
    Registry statusCompleted

  • Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

    NCT05494528 · start 2021-05-04

    Registered record
    Registry ID
    NCT05494528
    Conditions
    Chronic Hepatitis B Virus Infection
    Interventions
    Ropeginterferon alfa-2b; Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-05-04
    Completion
    2024-12-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B Virus Infection
    InterventionRopeginterferon alfa-2b; Entecavir
    PhaseNot applicable
    Registry statusUnknown

  • Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC

    NCT02650271 · start 2021-02-02

    Registered record
    Registry ID
    NCT02650271
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Entecavir; Tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-02-02
    Completion
    2023-12-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionEntecavir; Tenofovir
    PhasePhase 3
    Registry statusCompleted

  • Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

    NCT04680598 · start 2020-12-25

    Registered record
    Registry ID
    NCT04680598
    Conditions
    Hepatocellular Carcinoma
    Interventions
    ICI; Antiviral Prophylaxis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-12-25
    Completion
    2023-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionICI; Antiviral Prophylaxis
    PhaseNot recorded
    Registry statusUnknown

  • A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

    NCT04454567 · start 2020-11-11

    Registered record
    Registry ID
    NCT04454567
    Conditions
    Chronic Hepatitis B
    Interventions
    ABI-H0731; Placebo; NrtI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-11-11
    Completion
    2021-04-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionABI-H0731; Placebo; NrtI
    PhasePhase 2
    Registry statusTerminated

  • Synbiotics Interventions for Managing Cirrhosis and Its Complications

    NCT05687409 · start 2019-11-24

    Registered record
    Registry ID
    NCT05687409
    Conditions
    Cirrhosis, Liver; Metagonimiasis
    Interventions
    Entecavir 0.5 mg; A 10-g packet of lactulose oral solution and three capsules of probiotics; A 10-g packet of glucose oral solution and three capsules of starch
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-11-24
    Completion
    2022-10-24
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Metagonimiasis
    InterventionEntecavir 0.5 mg; A 10-g packet of lactulose oral solution and three capsules of probiotics; A 10-g packet of glucose oral solution and three capsules of starch
    PhasePhase 4
    Registry statusCompleted

  • A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

    NCT04129554 · start 2019-11-06

    Registered record
    Registry ID
    NCT04129554
    Conditions
    Hepatitis B, Chronic
    Interventions
    JNJ-73763989; JNJ-56136379; Placebo for JNJ-73763989; Placebo for JNJ-56136379; Entecavir (ETV) monohydrate; Tenofovir disoproxil fumarate (TDF); Tenofovir alafenamide (TAF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-11-06
    Completion
    2022-06-09
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionJNJ-73763989; JNJ-56136379; Placebo for JNJ-73763989; Placebo for JNJ-56136379 +3 more
    PhasePhase 2
    Registry statusCompleted

  • Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis

    NCT03945487 · start 2019-05-20

    Registered record
    Registry ID
    NCT03945487
    Conditions
    Decompensated Liver Cirrhosis
    Interventions
    umbilical cord-derived mesenchymal stem cell; Comprehensive treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-05-20
    Completion
    2023-12-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDecompensated Liver Cirrhosis
    Interventionumbilical cord-derived mesenchymal stem cell; Comprehensive treatment
    PhasePhase 2
    Registry statusUnknown